Frontiers in Immunology (Sep 2024)

Elevated levels of damage-associated molecular patterns HMGB1 and S100A8/A9 coupled with toll-like receptor-triggered monocyte activation are associated with inflammation in patients with myelofibrosis

  • Geraldine De Luca,
  • Geraldine De Luca,
  • Nora P. Goette,
  • Paola R. Lev,
  • Paola R. Lev,
  • Maria C. Baroni Pietto,
  • Maria C. Baroni Pietto,
  • Cecilia P. Marin Oyarzún,
  • Cecilia P. Marin Oyarzún,
  • Miguel A. Castro Ríos,
  • Beatriz Moiraghi,
  • Federico Sackmann,
  • Laureano J. Kamiya,
  • Laureano J. Kamiya,
  • Veronica Verri,
  • Victoria Caula,
  • Vanina Fernandez,
  • Angeles Vicente,
  • Julio Pose Cabarcos,
  • Vanesa Caruso,
  • Maria F. Camacho,
  • Irene B. Larripa,
  • Marina Khoury,
  • Rosana F. Marta,
  • Rosana F. Marta,
  • Ana C. Glembotsky,
  • Ana C. Glembotsky,
  • Paula G. Heller,
  • Paula G. Heller

DOI
https://doi.org/10.3389/fimmu.2024.1365015
Journal volume & issue
Vol. 15

Abstract

Read online

Inflammation plays a pivotal role in the pathogenesis of primary and post-essential thrombocythemia or post-polycythemia vera myelofibrosis (MF) in close cooperation with the underlying molecular drivers. This inflammatory state is induced by a dynamic spectrum of inflammatory cytokines, although recent evidence points to the participation of additional soluble inflammatory mediators. Damage-associated molecular patterns (DAMPs) represent endogenous signals released upon cell death or damage which trigger a potent innate immune response. We assessed the contribution of two prototypical DAMPs, HMGB1 and S100A8/A9, to MF inflammation. Circulating HMGB1 and S100A8/A9 were elevated in MF patients in parallel to the degree of systemic inflammation and levels increased progressively during advanced disease stages. Patients with elevated DAMPs had higher frequency of adverse clinical features, such as anemia, and inferior survival, suggesting their contribution to disease progression. Monocytes, which are key players in MF inflammation, were identified as a source of S100A8/A9 but not HMGB1 release, while both DAMPs correlated with cell death parameters, such as serum LDH and cell-free DNA, indicating that passive release is an additional mechanism leading to increased DAMPs. HMGB1 and S100A8/A9 promote inflammation through binding to Toll-like receptor (TLR) 4, whereas the former also binds TLR2. Monocytes from MF patients were shown to be hyperactivated at baseline, as reflected by higher CD11b and tissue factor exposure and increased expression levels of proinflammatory cytokines IL-1β and IL-6. Patient monocytes showed preserved TLR4 and TLR2 expression and were able to mount normal or even exacerbated functional responses and cytokine upregulation following stimulation of TLR4 and TLR2. Elevated levels of endogenous TLR ligands HMGB1 and S100A8/A9 coupled to the finding of preserved or hyperreactive TLR-triggered responses indicate that DAMPs may promote monocyte activation and cytokine production in MF, fueling inflammation. Plasma IL-1β and IL-6 were elevated in MF and correlated with DAMPs levels, raising the possibility that DAMPs could contribute to cytokine generation in vivo. In conclusion, this study highlights that, in cooperation with classic proinflammatory cytokines, DAMPs represent additional inflammatory mediators that may participate in the generation of MF inflammatory state, potentially providing novel biomarkers of disease progression and new therapeutic targets.

Keywords